Colin Bristow
Stock Analyst at UBS
(1.07)
# 3,641
Out of 4,876 analysts
99
Total ratings
31.03%
Success rate
-13.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $12 → $5 | $2.57 | +94.55% | 3 | Jun 17, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $1.2 → $1 | $0.44 | +128.73% | 6 | May 21, 2025 | |
| IMVT Immunovant | Downgrades: Neutral | $38 → $17 | $16.18 | +5.07% | 6 | Apr 22, 2025 | |
| AMGN Amgen | Maintains: Neutral | $315 → $319 | $280.61 | +13.68% | 9 | Apr 14, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $6 → $4 | $1.20 | +234.73% | 4 | Mar 28, 2025 | |
| ENGN enGene Holdings | Downgrades: Neutral | $34 → $7 | $3.54 | +97.74% | 2 | Feb 14, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $586 → $583 | $444.37 | +31.20% | 14 | Feb 11, 2025 | |
| PFE Pfizer | Maintains: Neutral | $29 → $28 | $24.30 | +15.23% | 13 | Feb 5, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $125 → $120 | $78.92 | +52.05% | 6 | Jan 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Buy | $47 → $71 | $49.60 | +43.16% | 3 | Dec 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $70 → $96 | $110.32 | -12.98% | 3 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $234 → $202 | $127.35 | +58.62% | 10 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $56 → $16 | $1.80 | +788.89% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $523.24 | +110.04% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $17.29 | +865.88% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $785.79 | -46.55% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $3.34 | -40.12% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $0.72 | +2,394.98% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $186.27 | -21.62% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $46.73 | +60.50% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $1.50 | +1,633.33% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.01 | +79.64% | 1 | Aug 23, 2021 |
Rocket Pharmaceuticals
Jun 17, 2025
Maintains: Buy
Price Target: $12 → $5
Current: $2.57
Upside: +94.55%
ALX Oncology Holdings
May 21, 2025
Maintains: Buy
Price Target: $1.2 → $1
Current: $0.44
Upside: +128.73%
Immunovant
Apr 22, 2025
Downgrades: Neutral
Price Target: $38 → $17
Current: $16.18
Upside: +5.07%
Amgen
Apr 14, 2025
Maintains: Neutral
Price Target: $315 → $319
Current: $280.61
Upside: +13.68%
Acumen Pharmaceuticals
Mar 28, 2025
Maintains: Buy
Price Target: $6 → $4
Current: $1.20
Upside: +234.73%
enGene Holdings
Feb 14, 2025
Downgrades: Neutral
Price Target: $34 → $7
Current: $3.54
Upside: +97.74%
Vertex Pharmaceuticals
Feb 11, 2025
Maintains: Buy
Price Target: $586 → $583
Current: $444.37
Upside: +31.20%
Pfizer
Feb 5, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $24.30
Upside: +15.23%
Merck & Co.
Jan 8, 2025
Maintains: Buy
Price Target: $125 → $120
Current: $78.92
Upside: +52.05%
PTC Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $47 → $71
Current: $49.60
Upside: +43.16%
Nov 21, 2024
Maintains: Neutral
Price Target: $70 → $96
Current: $110.32
Upside: -12.98%
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $127.35
Upside: +58.62%
Aug 9, 2024
Maintains: Neutral
Price Target: $56 → $16
Current: $1.80
Upside: +788.89%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $523.24
Upside: +110.04%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $17.29
Upside: +865.88%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $785.79
Upside: -46.55%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $3.34
Upside: -40.12%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $0.72
Upside: +2,394.98%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $186.27
Upside: -21.62%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $46.73
Upside: +60.50%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $1.50
Upside: +1,633.33%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $5.01
Upside: +79.64%